beclabuvir beclabuvir beclabuvir (also known by the research name bms-791325; abbreviated bcv) is an antiviral drug for the treatment of hepatitis c virus (hcv) infection that has been studied in clinical trials. in february 2017, bristol-myers squibb began sponsoring a post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function. from february 2014 to november 2016, a phase ii clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir (beclabuvir is referred to as bms-791325 in the trial) on patients infected with both hiv and hcv. furthermore, a recent meta-analysis of six published six clinical trials showed high response rates in hcv genotype 1-infected patients treated with daclatasvir, asunaprevir, and beclabuvir irrespective of ribavirin use, prior interferon-based therapy, or restriction on noncirrhotic patients, il28b genotype, or baseline resistance-associated variants beclabuvirclinical dataother namesbms-791325legal statuslegal status us: investigational new drug identifiers iupac name (1ar,12bs)-8-cyclohexyl-n-(dimethylsulfamoyl)-11-methoxy-1a--1,1a,2,12b-tetrahydrocyclopropaindolo benzazepine-5-carboxamide cas number958002-33-0pubchem cid56934415chemspider27289076uniimyw1x5co9skeggd10610 ychemical and physical dataformulac36h45n5o5smolar mass659.85 g·mol−13d model (jsmol)interactive image smiles cn1c2cc(c1)n2c(=o)34c3c5cc(ccc5-c6c(c7ccc(cc7n6c4)c(=o)ns(=o)(=o)n(c)c)c8ccccc8)oc inchi inchi=1s/c36h45n5o5s/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30h,5-9,11-12,18-21h2,1-4h3,(h,37,42)/t24-,25+,30-,36-/m0/s1key:zttkebysxucbse-qdfuakmasa-n pharmacology beclabuvir acts as a ns5b (rna polymerase) inhibitor.